Quick Takeaways
- BB BIOTECH AG filed SCHEDULE 13G/A for Sage Therapeutics, Inc. Common Stock (SAGE).
- Disclosed ownership: 1.9%.
- Date of event: 13 Jan 2025.
BB BIOTECH AG - 13 Jan 2025 SCHEDULE 13G/A Report for Sage Therapeutics, Inc. Common Stock (SAGE)
- Filing Manager
- BB BIOTECH AG
- Reporting Manager
- BB Biotech AG
- Security
- Sage Therapeutics, Inc. Common Stock
- Symbol
- SAGE
- Shares outstanding
- 62,026,474 shares
- Disclosed Ownership
- 1,178,503 shares
- Ownership
- 1.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Jan 2025, 06:02:29 UTC
- Date of event
- 13 Jan 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BB BIOTECH AG disclosed 1.9% ownership in Sage Therapeutics, Inc. Common Stock (SAGE) on 13 Jan 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Jan 2025, 06:02.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BB Biotech AG | 1.9% | 1,178,503 | 0 | 1,178,503 | /s/ Martin Gubler | Martin Gubler | |
| Biotech Target N.V. | 1.9% | 1,178,503 | 0 | 1,178,503 | /s/ Jan Bootsma | Jan Bootsma |